Want to see JP:2395 full AI Analyst Report?
2395 Stock Chart & Stats
¥1622.00
¥20.00(1.21%)
At close: 4:00 PM EST
¥1622.00
¥20.00(1.21%)
Day’s Range― - ―
52-Week Range¥1,067.00 - ¥2,005.00
Previous CloseN/A
Volume203.40K
Average Volume (3M)223.58K
Market Cap
¥54.95B
Enterprise Value¥71.79K
Total Cash (Recent Filing)¥14.33B
Total Debt (Recent Filing)¥37.58B
Price to Earnings (P/E)10.5
Beta0.82
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.71%
Share Statistics
EPS (TTM)129.00
Shares Outstanding41,632,400
10 Day Avg. Volume164,720
30 Day Avg. Volume223,580
Financial Highlights & Ratios
PEG Ratio-1.77
Price to Book (P/B)1.37
Price to Sales (P/S)1.81
P/FCF Ratio18.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,387.00Price Target Upside-14.49% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)94.9
Revenue Forecast (FY)¥38.37B
Bulls Say, Bears Say
Bulls Say
Solid ProfitabilityHealthy gross and net margins show that the company’s research services remain economically profitable despite recent normalization. This profitability provides resources to support operations, absorb moderate pressure, and preserve strategic flexibility over the next several quarters.
Outsourced Research ModelThe company serves pharmaceutical, biotechnology, and life-science customers by performing specialized work needed to advance drug candidates. Outsourcing supports a durable role in development programs, while project complexity and capacity utilization can support service revenue over time.
Expanded Asset BaseGrowth in equity and total assets indicates that the business has expanded its resource base alongside its operations. This can support laboratory capacity and continued service delivery, providing a foundation for future activity even as leverage requires monitoring.
Bears Say
Revenue And Margin PressureRecent revenue softness and material margin compression indicate that the company is moving through a weaker phase after stronger earlier performance. If this persists, slower operating leverage could limit earnings growth and reduce resources available for investment.
Rising LeverageDebt rising to roughly the level of equity increases balance-sheet sensitivity as profitability cools. Higher leverage can reduce financial flexibility, make results more exposed to operating setbacks, and constrain the company’s ability to fund expansion without additional financing.
Uneven Cash ConversionReported earnings have not consistently translated into discretionary cash, with weak operating conversion and several years of negative free cash flow. This volatility can limit internally funded investment and makes cash planning more dependent on working-capital or spending patterns.
Shin Nippon Biomedical Laboratories, Ltd. News
2395 FAQ
What was Shin Nippon Biomedical Laboratories, Ltd.’s price range in the past 12 months?
Shin Nippon Biomedical Laboratories, Ltd. lowest stock price was ¥1067.00 and its highest was ¥2005.00 in the past 12 months.
What is Shin Nippon Biomedical Laboratories, Ltd.’s market cap?
Shin Nippon Biomedical Laboratories, Ltd.’s market cap is ¥54.95B.
When is Shin Nippon Biomedical Laboratories, Ltd.’s upcoming earnings report date?
Shin Nippon Biomedical Laboratories, Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 48 days.
How were Shin Nippon Biomedical Laboratories, Ltd.’s earnings last quarter?
Shin Nippon Biomedical Laboratories, Ltd. released its earnings results on Aug 05, 2026. The company reported ¥25.55 earnings per share for the quarter.
Is Shin Nippon Biomedical Laboratories, Ltd. overvalued?
According to Wall Street analysts Shin Nippon Biomedical Laboratories, Ltd.’s price is currently Overvalued.
Does Shin Nippon Biomedical Laboratories, Ltd. pay dividends?
Shin Nippon Biomedical Laboratories, Ltd. pays a Semiannually dividend of ¥20 which represents an annual dividend yield of 3.71%. See more information on Shin Nippon Biomedical Laboratories, Ltd. dividends here
What is Shin Nippon Biomedical Laboratories, Ltd.’s EPS estimate?
Shin Nippon Biomedical Laboratories, Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shin Nippon Biomedical Laboratories, Ltd. have?
Shin Nippon Biomedical Laboratories, Ltd. has 41,632,400 shares outstanding.
What happened to Shin Nippon Biomedical Laboratories, Ltd.’s price movement after its last earnings report?
Shin Nippon Biomedical Laboratories, Ltd. reported an EPS of ¥25.55 in its last earnings report. Following the earnings report the stock price went up 9.135%.
Which hedge fund is a major shareholder of Shin Nippon Biomedical Laboratories, Ltd.?
Currently, no hedge funds are holding shares in JP:2395
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. operates as a global contract research organization (CRO), delivering comprehensive drug discovery and development services both in Japan and internationally. Its preclinical offerings encompass a wide array of laboratory services, including regulatory-compliant good laboratory practice (GLP) inspections. These studies cover general and specialized toxicity assessments, detailed pathological examinations, pharmacokinetic (PK) and pharmacodynamic (PD) analysis for biopharmaceuticals, immunotoxicity testing, and antibody production. The company also conducts investigations into reproductive and developmental toxicity, pharmacological mechanisms, and efficacy, alongside providing various imaging services. Furthermore, the organization specializes in developing and validating analytical methodologies, analyzing biological specimens, and determining pharmacokinetic parameters. It also conducts studies on absorption, distribution, metabolism, and excretion (ADME), often utilizing radioisotope-labeled compounds. Beyond preclinical and analytical work, it extends its expertise to clinical trial support through site management organization (SMO) services and broader clinical contract research organization (CRO) support. Its translational research division focuses on advancing novel medical solutions, such as the development of nasal drug delivery systems, nucleic acid-based adjuvants, and regenerative medicine therapies. Established in 1957, Shin Nippon Biomedical Laboratories, Ltd. maintains its headquarters in Tokyo, Japan.
2395 Stock 12 Month Forecast
Average Price Target
¥1,387.00
▼(-14.49% Downside)